Why the study?
ZAK is a promising target for drug discovery against hypertrophic cardiomyopathy, motivating the design of selective inhibitors.
Compound 6p is a potent and selective ZAK inhibitor that demonstrates promising in vivo efficacy against hypertrophic cardiomyopathy in a preclinical rat model.
ZAK is a new promising target for discovery of drugs with activity against antihypertrophic cardiomyopathy (HCM). A series of 1,2,3-triazole benzenesulfonamides were designed and synthesized as selective ZAK inhibitors. One of these compounds, 6p binds tightly to ZAK protein ( K d = 8.0 nM) and potently suppresses the kinase function of ZAK with single-digit nM (IC 50 = 4.0 nM) and exhibits excellent selectivity in a KINOMEscan screening platform against a panel of 403 wild-type kinases. This compound dose dependently blocks p38/GATA-4 and JNK/c-Jun signaling and demonstrates promising in vivo anti-HCM efficacy upon oral administration in a spontaneous hypertensive rat (SHR) model. Compound 6p may serve as a lead compound for new anti-HCM drug discovery.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: